News and Trends 20 Apr 2017 Norway Brings Another Cancer Vaccine to the Clinic Targovax has recruited its first patient in a Phase Ib trial for its new cancer vaccine TG02 targeting mutations of the RAS gene. Mutations of the RAS gene disrupt normal cell division and are a key driver of cancer progression and treatment resistance. The Norwegian biotech Targovax is developing peptide-based anti-cancer vaccines targeting these mutations found […] April 20, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 6 Apr 2017 UPDATE: Norwegian Stock Exchange hits Record Biotech IPO UPDATE (06/04/2017): BerGenBio has raised €43.55M, successfully beating a biotech record on the Norwegian stock exchange and setting its market cap at €135M. UPDATE (28/03/2017): BerGenBio has announced that the IPO could run up to €44M on Oslo Børs. It could become the Norway stock exchange’s biggest IPO in biotech, and indeed €44M would make it […] April 6, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2016 Investors bid on Nordic Nanovector’s Hottest Cancer Antibodies Nordic Nanovector has bagged €55M to push its pipeline forward through the clinic. Investors seem to be attracted by its ARC and ADC programs, using some of the hottest antibody technologies to treat cancer. Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat non-Hodgkin lymphoma (NHL) and recently entered the trending antibody-drug conjugate (ADC) field to fight against leukemia. These […] December 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2016 Can Oncolytic Viruses be the key to Treat Resistant Tumors? This week, we leave Belgium and keep traveling north to Oslo, where snow is starting to pack for the joy of skiers. Meanwhile, Targovax is there working hard to treat cancer with its immunotherapy pipeline. City: Oslo, Norway Founded: 2010 Employees: 20 – 30 Financial data: €12M raised in a private placement in July Mission: Targovax develops immuno-oncology […] November 18, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2016 Can this new Antibody-Drug Conjugate Collaboration make it to the Top? Nordic Nanovector is collaborating with Heidelberg Pharma to access the promising antibody-drug conjugate (ADC) technology. However, can it really take on the strong competition? Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat Non-Hodgkin Lymphoma (NHL) and other blood cancers. Today, the company has announced a collaboration with Wilex’ subsidiary Heidelberg Pharma to incorporate antibody-drug conjugates (ADCs) […] October 26, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email